Publications

5543 Results

Risk Prediction Model for Acute Care Use Among Advanced Cancer Patients on Clinical Trials

Authors
D Hershman;C Till;R Vaidya;M LeBlanc;J Unger
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 11074)
Year
2024
Research Committee(s)
Cancer Care Delivery

Upstream regulation of neurotransmitter signaling genes in metastatic colorectal cancer (mCRC) patients: data from CALGB/SWOG 80405 trial (Alliance) and MONSTAR-SCREEN-2

Authors
J Millstein;F Battaglin;Y Yang;S Soni;S Algaze;P Jayachandran;K Ashouri;P Mittal;L Torres-Gonzalez;W Zhang;F Ou;A Venook;F Innocenti;S Mumenthaler;T Hashimoto;T Fugisawa;Y Nakamura;H Bando;T Yoshino;H-J Lenz
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 3523)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Expression of metabolic genes associated with changes in brain structure across the lifespan affects patients (pts) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance)

Authors
F Battaglin;J Millstein;Y Yang;S Soni;S Algaze;K Ashouri;P Mittal;J Lo;L Torres-Gonzalez;P Jayachandran;W Zhang;F Ou;A Venook;F Innocenti;H-J Lenz
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 3144)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Prognostic impact of HER family expressions for metastatic colorectal cancer (mCRC): SCRUM-Japan MONSTAR-SCREEN-2 and CALGB/SWOG 80405 trial (Alliance) international collaboration

Authors
T Hashimoto;Y Nakamura;Y Yang;F Battaglin;F Innocenti;A Venook;A Makiyama;S Boku;N Machida;N Takahashi;S Kadowaki;Y Komatsu;T Kudo;E Oki;T Kato;Y Kagawa;T Fugisawa;H Bando;H-J Lenz;T Yoshino
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 3548)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Prospective “common arm” comparison of US SWOG S0424 and Japanese JME studies in early-stage non-small cell lung cancer (NSCLC): survival differences in the context of race, gender and smoking

Authors
P Mack;S Isa;M Hsieh;Y Koh;J Moon;A Tamiya;M Redman;K Albain;K Kelly;C Ambrosone;JE Gray;A Kubo;D Gandara;P Lara;T Kawaguchi
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 8036)
Year
2024
Research Committee(s)
Lung
Study Number(s)
S0424

Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153)

Authors
C Kyriakopoulos;Y Chen;R Jeraj;F Duan;J Luo;E Antonarakis;A Tripathi;D Kosoff;R Garje;R Pachynski;R Parikh;A Harzstark;N Adra;B Maughan;Y Zakharia;P Corn;G Liu;M Carducci
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), LBA, Oral Abstract Session; J Clin Oncol 42, 2024 (suppl 17; abstr LBA5000)
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/EA8153

Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT Trial

Authors
M Hennessy;C Gatsonis;H Jacene;R Connolly;B Burnette;E Stringer-Reasor;J Romanoff;A Taurone;C O'Sullivan;H Le-Petross;C Lawhn-Heath;V Stearns;A Fowler;S Tang;K Sepulveda;A DeMichelle;D Mankoff;A Wolff
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIP Poster;J Clin Oncol 42, 2024 (suppl 16; abstr TPS614)
Year
2024
Research Committee(s)
Breast

Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial

Authors
Y Abdou;J Hoag;W Barlow;J Gralow;F Meric-Berstam;K Albain;D Hayes;N Lin;E Perez;L Goldstein;S Chia;S Dhesy-Thind;P Rastogi;A Schott;J Racz;D Tripathy;G Hortobagyi;L Pusztai;P Sharma;K Kalinsky
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract; J Clin Oncol 42, 2024 (suppl 16; abstr 515)
Year
2024
Research Committee(s)
Breast
Study Number(s)
S1007

Time to target TIM-3 in colorectal cancer: TIM-3 expression to predict survival outcomes in patients in CALGB (Alliance)/SWOG 80405

Authors
S Algaze;Y Yang;J Millstein;F Battaglin;S Soni;P Mittal;K Ashouri;P Jayachandran;H Arai;J Ho Lo;W Zhang;L Torres-Gonzalez;A Wong;H-J Lenz
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster; J Clin Oncol 42, 2024 (suppl 16; abstr 3583)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)

Authors
C Rocha Lima;G Yothers;Puhalla;H Sanoff;D Cohen;K Guthrie;N Henry;P Ganz;S Kopetz;P Lucas;C Blanke;S Jacobs;T Hong;N Wolmark;H Hochster;T George;M Overman
Journal / Conference
ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIP poster; J Clin Oncol 42, 2024 (suppl 16; abstr TPS3632)
Year
2024
Research Committee(s)
Gastrointestinal